Chemours price target raised to $21 from $18 at Truist

Truist raised the firm’s price target on Chemours (CC) to $21 from $18 and keeps a Buy rating on the shares as part of a broader research note on Chemicals names. Shares have outperformed sector peers and the S&P over the last month, but the firm sees additional upside as it believes that the TiO2 industry is showing signs of incremental pricing discipline and production curtailments that, combined with continued implementations of anti-dumping duties targeting Chinese exports, have the potential to contribute to meaningful earnings growth, the analyst tells investors in a research note.